Revvity, Inc. is a leading provider of health science solutions, technologies, expertise, and services, delivering complete workflows from discovery to development, and diagnosis to cure. The company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, and diagnosis, and informatics. Revvity markets its products and services in over 160 countries.

• Employees: 11,500 (as of December 31, 2023)
• Geographic Footprint: More than 160 countries
• Headquarters: Waltham, Massachusetts
• Founded: Not explicitly stated in the 10K
• Number of locations/facilities: Not explicitly stated in the 10K
• Revenue: $2.75 billion (FY2023)
• Market Capitalization: Not explicitly stated in the 10K
• Key Subsidiaries/Brands: BioLegend

• CEO: Prahlad Singh
• CFO: Maxwell Krakowiak
• Senior Vice President, Administration, General Counsel and Secretary: Joel S. Goldberg
• Senior Vice President, Strategy and Business Development: Daniel R. Tereau
• Senior Vice President, Chief Commercial Officer: Miriame Victor
• Senior Vice President, Global Operations: Tajinder Vohra
• Vice President, Controller: Anita Gonzales

Key leaders have extensive experience in healthcare, strategy, and finance. Prahlad Singh has served as CEO since January 2019, Maxwell Krakowiak as CFO since August 2022, and Joel S. Goldberg as General Counsel since July 2008.

• Annual Revenue: $2.75 billion (FY2023)
• Net Income: $693.1 million (FY2023)
• Total Assets: $13.56 billion (as of December 31, 2023)
• Employees: 11,500 (as of December 31, 2023)
• Key Financial Highlights: Revenue decreased by 17% compared to FY2022, with Diagnostics segment revenue decreasing by 28%. Gross margins decreased to 56% in FY2023 from 60% in FY2022.

Revvity offers a broad range of products and services across two main segments:

• Life Sciences: Includes radiometric detection solutions, high-content screening systems, reagents for microscopy and imaging, live-cell imaging systems, image analysis platforms, multimode plate readers, homogeneous biochemical and cell-based reagents, cell lines, ELISA kits, bead-based reagents, in vivo imaging technologies, and cell counting systems.
• Diagnostics: Includes screening platforms for prenatal and maternal health, kits for detecting metabolic disorders in newborns, umbilical cord blood banking services, molecular-based infectious disease screening technologies, and instruments for sample processing and molecular extraction.

The company operates through two main segments:

• Life Sciences: Generated $1.29 billion in revenue in FY2023.
• Diagnostics: Generated $1.46 billion in revenue in FY2023.

Revvity's strategy focuses on developing and delivering innovative solutions in high-growth markets. Key initiatives include:

• Strengthening market position by expanding global product and service offerings.
• Attracting, retaining, and developing talent.
• Accelerating innovation through internal R&D and third-party collaborations.
• Augmenting growth through strategic acquisitions and licensing.
• Improving organizational efficiency and agility.
• Opportunistically utilizing share repurchase programs to drive shareholder value.

Revvity operates in the health science industry, serving pharmaceutical, biotech, contract research organizations, academic institutions, and diagnostic labs. The company faces competition from various domestic and foreign organizations, ranging from large multinational corporations to specialized firms. Key trends include rapid technological change, new product introductions, and evolving customer needs.

• Market Position: Leading provider of health science solutions.
• Key Competitors: Not explicitly stated in the 10K.
• Industry Trends: Rapid technological change, frequent new product introductions, and evolving customer needs.

• Market Risks: Decline in markets, uncertainties in government funding, and unfavorable changes in regulations.
• Operational Risks: Global economic and political conditions, operational disruptions at facilities, supply chain disruptions, and reliance on single-source suppliers.
• Financial Risks: Fluctuations in quarterly operating results, inability to compete effectively, and failure to realize the full value of intangible assets.
• Regulatory Risks: Failure to comply with regulations, product liability claims, and changes in healthcare regulations.
• Intellectual Property Risks: Inability to protect intellectual property, loss of licensed rights, and infringement claims.